Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Low Dose Rituximab Consolidation in CLL
NCT01521689Phase 2Unknown
- Sponsor
- Institut Paoli-Calmettes
- Start
- Dec 2011
- Primary completion
- Jun 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in chronic lymphocytic leukemia (CLL), sponsored by Institut Paoli-Calmettes. Status: unknown.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01521689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01521689.